Role for sentinel lymph node dissection in the management of large (≥5 cm) invasive breast cancer

被引:49
作者
Chung, MH [1 ]
Ye, W [1 ]
Giuliano, AE [1 ]
机构
[1] St Johns Hlth Ctr, John Wayne Canc Inst, Joyce Eisenberg Keefer Breast Ctr, Santa Monica, CA 90404 USA
关键词
sentinel lymph node dissection; breast carcinoma; axillary staging; neoadjuvant chemotherapy;
D O I
10.1245/aso.2001.8.9.688
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Sentinel lymph node dissection (SLND) for small, early-stage breast cancer is well accepted. However, the role of SLND for large primary breast cancer is controversial. We investigated the feasibility and clinical applicability of SLND in patients with large (greater than or equal to5 cm) breast cancers and clinically negative axillae. Methods: A prospectively entered database was used to identify all patients who underwent surgical management of histopathologically confirmed primary breast carcinomas greater than or equal to5 cm in diameter between September 1991 and August 2000. Patients who had clinically negative axillae and underwent SLND followed by completion axillary lymph node dissection (ALND) were selected for the study. The positivity rate, accuracy rate, and false-negative rate of SLND were determined. Results: Of the 41 patients selected for the study, 24 had infiltrating ductal carcinoma and 17 had infiltrating lobular carcinoma. Mean tumor size was 7.12 cm (range, 5-23 cm). At least one sentinel lymph node (SLN) was identified in all cases. Thirty patients had tumor-positive SLNs. Axillary metastasis was also identified in one patient who did not have a positive SLN. Thus, SLN status accurately predicted regional nodal status in 98% (40 of 41) of cases. The false-negative rate of SLND was 3% (1 of 31). None of the three patients with SLN micrometastasis, defined as a tumor focus less than or equal to2 mm, had tumor deposits in nonsentinel axillary lymph nodes. Only SLN macrometastasis (>2-mm tumor deposit) and primary tumor size greater than or equal to7 cm. predicted nonsentinel axillary metastasis with significance on multivariate analysis (P = .008 and P = .046, respectively). Conclusions: SLND is feasible and accurate in patients with large breast cancers and clinically negative axillae. Axillary lymph node dissection can be avoided in nearly one third of patients by focused examination of the SLN.
引用
收藏
页码:688 / 692
页数:5
相关论文
共 28 条
[1]  
Bedrosian I, 2000, CANCER, V88, P2540, DOI 10.1002/1097-0142(20000601)88:11<2540::AID-CNCR16>3.0.CO
[2]  
2-A
[3]   PRIMARY CHEMOTHERAPY TO AVOID MASTECTOMY IN TUMORS WITH DIAMETERS OF 3 CENTIMETERS OR MORE [J].
BONADONNA, G ;
VERONESI, U ;
BRAMBILLA, C ;
FERRARI, L ;
LUINI, A ;
GRECO, M ;
BARTOLI, C ;
DEYOLDI, GC ;
ZUCALI, R ;
RILKE, F ;
ANDREOLA, S ;
SILVESTRINI, R ;
DIFRONZO, G ;
VALAGUSSA, P .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (19) :1539-1545
[4]  
Botti C, 1995, J Am Coll Surg, V181, P202
[5]  
Brenin DR, 1998, SEMIN ONCOL, V25, P13
[6]   Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? [J].
Chu, KU ;
Turner, RR ;
Hansen, NM ;
Brennan, MB ;
Bilchik, A ;
Giuliano, AE .
ANNALS OF SURGERY, 1999, 229 (04) :536-541
[7]   Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy [J].
Cohen, LF ;
Breslin, TM ;
Kuerer, HM ;
Ross, MI ;
Hunt, KK ;
Sahin, AA .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2000, 24 (09) :1266-1272
[8]   The efficacy of neoadjuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer [J].
Cunningham, JD ;
Weiss, SE ;
Ahmed, S ;
Bratton, JM ;
Bleiweiss, IJ ;
Tartter, PI ;
Brower, ST .
CANCER INVESTIGATION, 1998, 16 (02) :80-86
[9]  
Dent DM, 1996, ARCH SURG-CHICAGO, V131, P1125
[10]   Effect of preoperative chemotherapy on the outcome of women with operable breast cancer [J].
Fisher, B ;
Bryant, J ;
Wolmark, N ;
Mamounas, E ;
Brown, A ;
Fisher, ER ;
Wickerham, DL ;
Begovic, M ;
DeCillis, A ;
Robidoux, A ;
Margolese, RG ;
Cruz, AB ;
Hoehn, JL ;
Lees, AW ;
Dimitrov, NV ;
Bear, HD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2672-2685